Topamax
FDA Issues Topamax Warning
A Topamax Warning has been issued by the FDA concerning new data that links Topamax , an antiseizure drug to increased risk of birth defects if used during pregnancy. The FDA Warning is due to data that shows showed a higher risk for cleft lip and cleft palate in infants . The FDA’s Topamax warning is requesting that Medical professionals warn patients of childbearing age about the potential hazards.
The Topamax Warning from the FDA is based on new data showing that 1.4% of infants exposed to Topamax during their first trimester had Cleft Palate as compared to .07% without the drug.
Johnson & Johnson had sales of $2.7 billion from Topamax for in 2008. The company pleaded guilty last year of promoting Topamax for unapproved uses, and had to pay $81.5 million fine.
Topamax Lawyers are now investigating a Topamax Lawsuit. The Topamax lawsuits allege that Johnson and Johnson failed to identify the risks of Topamax causing injuries to unborn children. The lawsuits would allege that the manufacture knew or should have known about problems such as Cleft Palate in infants And Instead of researching the dangers that Topamax can cause, the drug was instead marketed and sold for weight loss, alcohol dependence, eating disorders and mood and anxiety disorders without understanding the side effects.
There is now little question that there is a large increased risk of birth defects in infmats whose mothers were talking Topamax during pregnancy. If you believe your child was harmed from Topamaz, you should contact a Topamax Lawyer now.
Related TopamaxTopics
Our e-Newsletter
Latest FDA Alerts
-
FDA Issues Stryker Hip Recall
The FDA annouced on July 6th, that Stryker has announced a voluntary recall of its modular neck...
-
Hip Replacement Device Failures
Hip Replacement Recall Announced DePuy Orthopaedics, a unit of Johnson & Johnson, announced the...
-
Robot Surgery FDA Warning
Innovative Surgical, the manufacture of the Da Vinci Surgery Robot recieved a warning letter from FDA...